CelLBxHealth plc shares trade on the Alternative Investment Market (AIM) of the London Stock Exchange.
The Board is committed to maintaining high standards of corporate governance appropriate to the size, stage of development and strategic focus of the Company. The Company has adopted the Quoted Companies Alliance Corporate Governance Code (QCA Code 2023) as its governance framework and believes that effective governance supports long-term shareholder value, responsible decision-making and sustainable growth.
The Board is collectively responsible for the long-term success of the Company and provides oversight of strategy, risk management, internal controls and corporate culture. During 2025, the Company undertook a significant strategic and operational transformation, transitioning to a commercially focused, partner-led and capital-efficient business model. In parallel, the Board and leadership team were strengthened through the appointment of new Executive and Non-Executive Directors with extensive experience across diagnostics, life sciences, healthcare, finance and capital markets.
The Board comprises two Executive Directors and three Non-Executive Directors, one of whom is considered independent. The Board is supported by an Audit Committee and a combined Nomination & Remuneration Committee operating under formally delegated terms of reference.
The Company applies the ten principles of the QCA Code 2023 and provides explanations on how these principles support the Company’s strategy, governance framework and long-term objectives. These include:
- establishing a clear purpose, strategy and business model;
- promoting a culture based on ethical values and behaviors;
- engaging effectively with shareholders and wider stakeholders;
- embedding effective risk management and internal controls;
- maintaining a balanced and effective Board; and
- supporting long-term value creation through appropriate governance and remuneration structures.
The Board recognises the importance of stakeholder engagement and fulfils its duties under Section 172 of the Companies Act 2006 by considering the long-term impact of decisions on shareholders, employees, customers, suppliers, partners and other stakeholders. Stakeholder perspectives are considered through regular investor engagement, employee interaction, customer and partner dialogue and ongoing review of operational and financial performance metrics.
Further details on the Company’s governance framework, Board Committees, risk management processes and application of the QCA Code 2023 are set out in the Corporate Governance Report within the 2025 Annual Report and Financial Statements.
This governance statement was last reviewed and updated in May 2026.
Executive Chairman's statement
At CelLBxHealth plc, we are committed to building long-term shareholder relationships based on transparency, accountability and clear communication.
2025 was a year of transition for the Company. Following a strategic review, CelLBxHealth repositioned the business towards a commercially focused, partner-led and capital-efficient model designed to accelerate growth and strengthen long-term value creation.
The Company also strengthened its leadership team and Board, while implementing significant operational efficiencies to create a leaner and more focused organization.
Our strategy is centered on expanding adoption of our circulating tumor cell (CTC) platform through partnerships with leading diagnostics companies, including QIAGEN, Roche Diagnostics, and Illumina, supporting broader commercial adoption across research and clinical markets.
The Board remains confident in the long-term potential of the Company’s technology and market opportunity. We believe strong corporate governance is fundamental to sustainable growth, and CelLBxHealth continues to apply the QCA Code 2023 as the foundation of its governance framework.